Cardiopulmonary bypass (CPB) is essential for the conduct of open-heart procedures. While lifesaving, CPB can be associated with significant end-organ injuries believed to result from inflammatory responses triggered by the extracorporeal surfaces encountering cellular elements in the blood stream. In this review, we discuss the role of interleukin-6 (IL-6) and the potential for Tocilizumab, an anti-IL-6 receptor antibody, in mitigating these effects. We compare the inflammatory responses in CPB and cytokine storm, a clinical condition in which Tocilizumab has been effectively implemented. Finally, we examine why corticosteroids, used to reduce the morbidity of CPB, may not effectively reduce IL-6 levels.
FerreiraLOVasconcelosVWLimaJ de S, et al.Biochemical changes in cardiopulmonary bypass in cardiac surgery: new insights. J Pers Med.2023;13(10):1506. doi: https://doi.org/10.3390/jpm 13101506
2.
CaseyLC. Role of cytokines in the pathogenesis of cardiopulmonary-induced multisystem organ failure. Ann Thorac Surg. 1993;56(5):S92-S96.
3.
CuiAHuangTLiS, et al.Dictionary of immune responses to cytokines at single-cell resolution. Nature2023;625(7994):377-384.
4.
GueretGLionFGuriecN, et al.Acute renal dysfunction after cardiac surgery with cardiopulmonary bypass is associated with plasmatic IL6 increase. Cytokine. 2009;45(2):92-98.
5.
LiuKDAltmannCSmitsG, et al.Serum interleukin-6 and interleukin-8 are early biomarkers of acute kidney injury and predict prolonged mechanical ventilation in children undergoing cardiac surgery: a case-control study. Crit Care. 2009;13(4):R104. doi: https://doi.org/10.1186/cc7940.
6.
BronickiRAHallM. Cardiopulmonary bypass-induced inflammatory response: pathophysiology and treatment. Pediatr Crit Care Med.2016;17(8):S272-S278.
7.
RisnesIWagnerKUelandTMollnesTEAukrustPSvennevigJL.Interleukin-6 may predict survival in extracorporeal membrane oxygenation treatment. Perfusion. 2008;23(3):173-178.
8.
GuptaMJohann-LiangRSisonCPQuaegebeurJFriedmanDM. Relation of early pleural effusion after pediatric open heart surgery to cardiopulmonary bypass time and systemic inflammation as measured by serum interleukin-6. Am J Cardiol.2001;87(10):1220-1223.
9.
AllanCKNewburgerJWMcGrathE, et al.The relationship between inflammatory activation and clinical outcome after infant cardiopulmonary bypass. Anesth Analg. 2010;111(5):1244-1251.
10.
JensenEAndréassonSBengtssonA, et al.Influence of two different perfusion systems on inflammatory response in pediatric heart surgery. Ann Thorac Surg. 2003;75(3):919-925.
11.
MarkewitzAFaistIEWeinholdC, et al.Alterations of cell-mediated immune response following cardiac surgery. Eur J Cardiothorac Surg.1993;7(4):193-199.
12.
SohnNMarcouxJMycykTKrahnJMengQ.The impact of different biocompatible coated cardiopulmonary bypass circuits on inflammatory response and oxidative stress. Perfusion. 2009;24(4):231-237.
13.
Curi-CuriPJAlanisEACalderón- ColmeneroJ, et al.Impact of modified ultrafiltration in congenital heart disease patients treated with cardiopulmonary bypass. Congenit Heart Dis.. 2018;1(1):49.
14.
GrünenfelderJZündGSchoeberleinA, et al.Modified ultrafiltration lowers adhesion molecule and cytokine levels after cardiopulmonary bypass without clinical relevance in adults. Eur J Cardiothorac Surg.2000;17(1):77-83.
15.
BerdatPAEichenbergerEEbellJ, et al.Elimination of proinflammatory cytokines in pediatric cardiac surgery: analysis of ultrafiltration method and filter type. J Thorac Cardiovasc Surg. 2004;127(6):1688-1696.
16.
DeptulaJGlogowskiKMerriganK, et al.Evaluation of biocompatible cardiopulmonary bypass circuit use during pediatric open-heart surgery. J Extra Corpor Technol. 2006;38(1):22-26.
17.
HillKDKannankerilPJJacobsJP, et al.Methylprednisolone for heart surgery in infants—a randomized, controlled trial. N Engl J Med. 2022;387(23):2138-2149.
18.
GrahamEMMartinRHBuckleyJR, et al.Corticosteroid therapy in neonates undergoing cardiopulmonary bypass: randomized controlled trial. J Am Coll Cardiol. 2019;74(5):659-668.
19.
LomivorotovVKornilovIBoboshkoV, et al.Effect of intraoperative dexamethasone on major complications and mortality among infants undergoing cardiac surgery: the DECISION randomized clinical trial. JAMA. 2020;323(24):2485-2492.
20.
Keski-NisulaJSuominenPKOlkkolaKT, et al.Effect of timing and route of methylprednisolone administration during pediatric cardiac surgical procedures. Ann Thorac Surg. 2015;99(1):180-185.
21.
Ter HorstRJaegerMSmeekensSP, et al.Host and environmental factors influencing individual human cytokine responses. Cell. 2016;167(4):1111-1124.
22.
OlnesMJKotliarovYBiancottoA, et al.Effects of systemically administered hydrocortisone on the human immunome. Sci Rep.2016;6(1):1-15.
RovitoRBonoVAugelloM, et al.Association between SARS-CoV-2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID-19 patients. Sci Rep.2022;12(1):1-11.
25.
Giamarellos-BourboulisEJNeteaMGRovinaN, et al.Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992-1000.e3.
26.
ChoustermanBGSwirskiFKWeberGF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39(5):517-528.
27.
CaricchioR.GalluciSSystemic lupus erythematosus and cytokine storm.Adv Exp Med Biol. 2024:355-364.
28.
ElemamNMMaghazachiAAHannawiS. COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies. Curr Med Res Opin. 2021;37(6):929-938.
29.
ZhangHLvXKongQTanY. IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro. Hum Vaccin Immunother. 2022;18(1):1-14.
30.
GruppSAKalosMBarrettD, et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1527.
Rose-JohnSLeonardWJSchreiberRD.Interleukin-6 family cytokines. Cold Spring Harb Perspect Biol. 2018;10(2):a028415.
33.
McElvaneyOJCurleyGFRose-JohnSMcElvaneyNG. Interleukin-6: Obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med. 2021;9(6):643-654.
34.
JohnsonDEO’KeefeRAGrandisJR. Targeting the IL-6/JAK/STAT3 signaling axis in cancer. Nat Rev Clin Oncol.2018;15(4):234-248.
35.
LiuzziJPLichtenLARiveraS, et al.Interleukin-6 regulates the zinc transporter Zip14 in liver and contributes to the hypozincemia of the acute-phase response. Proc Natl Acad Sci U S A. 2005;102(19):6843-6848.
36.
HiranoTYasukawaKHaradaH, et al.Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986;324(6092):73-76.
37.
IshibashiTKimuraHShikamaY, et al.Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 1989;74(4):1241-1244.
38.
JawaRSAnilloSHuntoonKBaumannHKulaylatM.Interleukin-6 in surgery, trauma, and critical care part II: clinical implications. J Intensive Care Med.2010;26(2):73-87.
39.
HalterJSteinbergJFinkG, et al.Evidence of systemic cytokine release in patients undergoing cardiopulmonary bypass. J Extra Corpor Technol. 2005;37(3):272-277.
40.
WhittenCWHillGEIvyRGreilichPELiptonJM.Does the duration of cardiopulmonary bypass or aortic cross-clamp, in the absence of blood and/or blood product administration, influence the IL-6 response to cardiac surgery?Anesth Analg. 1998;86(1):28-33.
41.
FinkelMSOddisCVJacobTDWatkinsSCHattlerBGSimmonsRL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257(5068):387-389.
42.
ShettyAHansonRKorstenP, et al.Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des Devel Ther. 2014;8:349-364.
43.
YokotaSTanakaTKishimotoT. Efficacy, safety, and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis. 2012;4(6):387-397.
44.
RegolaFCerudelliEBosioG, et al.Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients. Rheumatol Adv Pract. 2020;4(2):rkaa017. doi: https://doi.org/10.1093/rap/rkaa017
45.
Rubbert-RothAFurstDENebeskyJMJinABerberE.A review of recent advances using tocilizumab in the treatment of rheumatic diseases. Rheumatol Ther. 2018;5(1):21-42.
46.
MeyerMASWibergSGrandJ, et al.Treatment effects of interleukin-6 receptor antibodies for modulating the systemic inflammatory response after out-of-hospital cardiac arrest (the IMICA trial): A double-blinded, placebo-controlled, single-center, randomized, clinical trial. Circulation. 2021;143(19):1841-1851.
47.
Fernández-RuizI. Early inhibition of IL-6 signaling after an acute MI improves myocardial salvage. Nat Rev Cardiol.2021;18(7):460-460.
48.
LewisTCArnoukSToyB, et al.Tocilizumab accelerates recovery in patients with severe COVID-19 pneumonia on venovenous extracorporeal membrane oxygenation. ASAIO J.2022;68(8):1010-1016.
49.
KhannaDLinCJFFurstDE, et al.Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: open-label extension of a phase 3 randomized controlled trial. Am J Respir Crit Care Med. 2022;205(6):674-684.
50.
LeeDWGardnerRPorterDL,et al.Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188-195.
51.
Tocilizumab (Actemra): Adult Patients with Moderately to Severely Active Rheumatoid Arthritis [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug. Table 1, Cost-Comparison Table for Biologic Disease-Modifying Drugs for Rheumatoid Arthritis. https://www.ncbi.nlm.nih.gov/books/NBK349513/table/T43/Accessed 10/13/2024
BrocaFSouchaud-DebouverieOLiuuERoblotPMartinM. Severe infections in patients treated with tocilizumab for systemic diseases other than rheumatoid arthritis: a retrospective multicenter observational study. Eur J Rheumatol. 2023;10(1):18-22.
54.
LiuHNiuCElkhaperyA, et al.Infectious complications after tocilizumab in patients with COVID: a real-world experience. Chest. 2022;162(4):A432-A433.
55.
MooreJLStroeverSJRondainPEScatenaRN.Incidence of secondary bacterial infections following utilization of tocilizumab for the treatment of COVID-19—a matched retrospective cohort study. J Glob Infect Dis. 2021;13(2):67-71..
56.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Tocilizumab. [Updated 2021 May 11]. https://www.ncbi.nlm.nih.gov/books/NBK548243/A. Accessed 10/13/2024.
